Clinical trial
A Phase IIc, Open-Label, Randomized Controlled Trial of Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis (PRESCIENT)
NCT05556746 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIc, Open-Label, Randomized Controlled Trial of Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible Tuberculosis (PRESCIENT)
- Lead sponsor
- Brigham and Women's Hospital
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- November 24, 2023
- Completion date
- January 31, 2027
- Enrollment
- 94 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.